D
eep sedation with barbiturates or propofol is a wellestablished standard therapy for patients with critically elevated intracranial pressure. Since immunosuppressive side effects of barbiturates have been reported in vitro, there is growing clinical concern about potentially increased risks of infectious complications from barbiturates. Clinical studies remain inconclusive, since the disposition for infectious complications in severely brain traumatized patients is multifactorial and accompanied by a variety of confounding factors (1) (2) (3) (4) . Nonetheless, the specific immunomodulatory effects of drugs are relevant but difficult to define in a clinical setting.
In vitro, barbiturates have been shown to affect various components of the immune response, such as cytokine release, chemotaxis, respiratory burst, and phagocytosis (5) . These studies, however, report inconsistent results, especially for leukocyte phagocytosis (6, 7) . The application of various stimuli, such as latex beads, heat-inactivated bacteria, or Escherichia coli, as well as the application of different models might contribute to these differences. Gram-negative bacteria like E. coli and Gram-positive pathogens like Staphylococcus aureus activate different mechanisms of bacterial ingestion. Therefore, data on phagocytosis cannot be extrapolated from one pathogen to an other.
Furthermore, there is still a lack of clinically relevant models, such as phagocytosis of viable bacteria, and there are also no studies systematically investigating dose-effect relationships. Due to the diversity of the existing studies, conclusive interpretations and comparisons of the inhibitory potency of barbiturates are still very difficult.
Clinically, S. aureus represents one of the most important pathogens in critically ill patients and most particularly in the subset of brain-injured patients (8 -10 ). An increased disposition for pulmonary infections caused by S. aureus has been reported repeatedly, mirrored by a significantly higher incidence than in other trauma patterns (8) . We therefore selected S. aureus to investigate the potential side effects of different sedatives at increasing concentrations.
The aim of this study was to investigate whether the reported immunomodulatory effects of barbiturates affect phagocytosis of live S. aureus in a comparable manner. We hypothesized that the effects on S. aureus phagocytosis are dose-dependent and differ in terms of inhibitory potency depending on whether 
MATERIALS AND METHODS
Blood Samples and Study Subjects. The study protocol was in compliance with the Helsinki Declaration and approved by the institutional review board. Written informed consent was obtained from each volunteer.
Phagocytosis assays were performed as previously described with slight modifications (11) . In brief, 10-mL blood samples were taken from ten healthy volunteers aged 32.5 Ϯ 7 yrs and heparinized with 5 units/mL heparin sodium (Vetren 200 Altana, Konstanz, Germany). Then 100 L of each sample was used for leukocyte counts using trypan blue solution with 3% acetic acid for the lysis of red blood cells. The remaining blood was divided into volumes of 2 mL and mixed with different concentrations of anesthetics or with isotonic saline as control. Blood samples were incubated with the different concentrations of anesthetics for 30 mins at 37°C.
Anesthetics. We decided to study a wide range of anesthetic concentrations that had been reported in clinical settings. For all anesthetics, the lowest concentration was selected according to plasma levels described in the literature for patients with raised intracranial pressure treated by deep barbiturate sedation (12) (13) (14) (15) . For propofol we chose plasma levels obtained during sedation of ICU patients and in patients with elevated intracranial pressure (16, 17) . Then, concentrations exceeding these values by a factor of ten and 100 were chosen.
Preliminary results showed no effect of thiopentone at concentrations corresponding to the clinical concentration and its ten-fold, whereas for methohexitone inhibitory effects were already observed at ten times the clinical concentration. We therefore decided to investigate higher concentrations of thiopentone, beginning at the 100-fold clinical concentration, to be able to compare the dose-dependent effects of the two barbiturates.
Different concentrations of thiopentone (Trapanal, Altana, Konstanz, Germany), methohexitone (Brevimythal 660, Lilly, Gie␤en, Germany), and propofol (Disoprivan 1%, Astra Zeneca, Wedel, Germany) were diluted in isotonic saline to a total volume of 100 L for each sample. Final concentrations of anesthetics in whole blood samples were 7.6 ϫ 10 Ϫ3 M, 9.5 ϫ 10 Ϫ3 M, and 1.9 ϫ 10 Ϫ2 M for thiopentone; 1.1 ϫ 10 Ϫ4 M, 1.1 ϫ 10 Ϫ3 M, and 1.1 ϫ 10 Ϫ2 M for methohexitone, and 1 ϫ 10 Ϫ5 M, 1 ϫ 10 Ϫ4 M and 1 ϫ 10 Ϫ3 M for propofol. The pH was adjusted to 7.4 in all experiments. Eight independent experiments were carried out for each anesthetic concentration.
Bacteria. S. aureus (ATCC 25923) was grown in tryptone soy broth (Oxoid, Wesel, Germany) for 3 hrs and centrifuged at 375 ϫ g for 5 mins. Pellets were resuspended in phosphate-buffered saline (without calcium or magnesium; Sigma, Deisenhofen, Germany) and then washed twice. For the detection of intracellular bacteria by flow cytometry, pellets were incubated with calcein AM (calcein AM special packing, Molecular Probes, Eugene, OR) for 50 mins at 37°C. Stained bacteria were washed twice with phosphatebuffered saline and adjusted to final concentrations of 2 ϫ 10 9 colony-forming units/mL. Bacterial counts were performed by plating appropriate dilutions of bacterial suspensions on mannitol salt agar (Oxoid, Wesel, Germany); colony-forming units were counted after 24 hrs of incubation at 37°C. Repeated assays were performed to ascertain stable fluorescence intensity and bacterial viability during all experiments.
Phagocytosis. For each assay, bacteria were adjusted to a constant ratio of 25:1 (bacteria/leukocytes) based on whole blood leukocyte counts. The culture medium was RPMI (RPMI 1640, Sigma) containing 10% autologous serum for preopsonization of bacteria for faster phagocytosis. Diluted bacteria and anesthetic-treated whole blood samples were incubated separately for 30 mins at 37°C. Bacteria were then added to the blood samples and incubated at 37°C for 2.5, 5, 10, 20, and 40 mins before phagocytosis was stopped by adding N-ethyl maleimide (10 mM, Sigma). Between these steps, samples were stored on ice.
Granulocytes were then stained with the monoclonal antibody directed against CD13 (myeloid cell CD13 RPE, DAKO, Glostrup, DK) for flow cytometric detection, followed by lysis of erythrocytes (FACS Lysing Solution, Becton Dickinson, Heidelberg, Germany). Samples were centrifuged (375 ϫ g for 5 mins), resuspended in phosphate-buffered saline, and kept on ice until flow cytometric analysis.
Flow Cytometry. Flow cytometric analysis was performed using a FACS SORT system (Becton Dickinson). Lymphocytes and cell debris were excluded from the analysis using a threshold on low angle forward scatter. Free bacteria were also excluded by this threshold because of their small size. Granulocytes were differentiated from monocytes by their fluorescence signal and their scatter properties. To define the cutoff for positive fluorescence of the monoclonal antibody, we used an isotype control (mouse immunoglobulin IgG-1-RPE, Caltag, San Francisco, CA). Likewise, unstained bacteria were used as control for calcein AM stained bacteria to exclude autofluorescence phenomena from the bacteria.
Statistical Analysis. Phagocytosis was determined as a) granulocyte recruitment Ϫ the ratio of granulocytes ingesting bacteria to the total number of granulocytes; and b) phagocytosis activity Ϫ fluorescence intensity of intracellular bacteria as a semiquantitative measurement of bacterial uptake. At least 10,000 granulocytes were analyzed for each data point. Data are reported as mean Ϯ SD.
Statistical analysis was performed with the Kolmogorov-Smirnov test, which confirmed normal distribution, and analysis of variance. Blood donors were included as random factors, and time was entered as fixed point for the analysis of variation. Student's t-test was applied to compare differences between the groups at different time points; p Ͻ .05 was considered significant. Where appropriate, an adjustment of ␣ according to Bonferroni Holm was applied.
To determine inhibitory concentrations for barbiturates, concentration-response curves were fitted for the data at 40 mins following a logistic function from the Hill equation: y ϭ amin ϩ (amax Ϫ amin) · [1 Ϫ xn/(ϫ50n ϩ xn)], where amax and amin were defined as the maximum and minimum obtained, n is the Hill coefficient, and ϫ50 is the half-maximal inhibitory concentration.
RESULTS
Thiopentone. Thiopentone affected neither granulocyte recruitment nor phagocytosis activity at low concentrations, which correspond to concentrations found in patients and the ten-fold of these values (data not shown).
With increasing concentrations beginning at 100-fold of the clinically found concentration (7.6 ϫ 10 Ϫ3 M), thiopentone significantly reduced granulocyte recruitment in a dose-dependent manner. At 7.6 ϫ 10 Ϫ3 M, a significant retardation of granulocyte recruitment oc-
Ϫ3 M thiopentone, granulocyte recruitment was significantly reduced over the whole investigated time-range; the maximal effect (Ͻ20% granulocyte recruitment compared with controls) was observed at the highest concentration (1.9 ϫ 10 Ϫ2 M, p Ͻ .008 at all time points).
Phagocytosis activity was also found to be suppressed from concentrations starting at 7.6 ϫ 10 Ϫ3 M. At 7.6 ϫ 10 Ϫ3 M, significant retardation was observed at 5, 10, and 20 mins (p Ͻ .04), but the values found at 40 mins did not differ from controls. At concentrations of 9.5 ϫ 10 Ϫ3 M and 1.9 ϫ Ϫ2 M, phagocytosis activity was found to be significantly reduced at 5, 10, 20, and 40 mins (p Ͻ .035), with a maximal effect of Ͻ5% of the phagocytosis activity of controls at the highest concentration (Fig. 1) .
Methohexitone. Methohexitone significantly attenuated granulocyte recruitment and phagocytosis activity beginning at 1.1 ϫ 10 Ϫ3 M, which corresponded approximately to ten times the plasma levels found in patients. Granulocyte recruitment was significantly inhibited at 10, 20, and 40 mins (p Ͻ .045 all). In contrast, for thiopentone in the lowest inhibiting concentration, only a retardation of granulocyte recruitment was observed at 2.5 and 5 mins. At 1.1 ϫ 10 Ϫ2 M methohexitone, granulocyte recruitment was significantly suppressed to Ͻ20% of that of controls at 5, 10, 20, and 40 mins (p Ͻ .0002 for all time points).
Phagocytosis activity was also significantly attenuated beginning at a concentration of 1.1 ϫ 10 Ϫ3 M. This was observed at 10, 20, and 40 mins (p Ͻ .0001 for all time points). Again, no retardation was seen as with thiopentone in the lowest inhibitory concentration. The maximal effect, Ͻ5% phagocytosis activity of controls, was observed at the highest concentration of 1.1 ϫ 10 Ϫ2 M methohexitone at 10, 20, and 40 mins (p Ͻ .0001 in each case), as shown in Figure 2 .
Propofol. Propofol affected neither granulocyte recruitment nor phagocytosis activity at any of the investigated concentrations (Fig. 3) .
Dose-Dependent Effects. Since both barbiturates showed a strong inhibition of granulocyte recruitment and phagocytosis activity, dose-response curves were fitted to compare the observed effects. Whereas methohexitone showed a gradually increasing inhibition over the investigated dose range of 1.1 ϫ 10 Ϫ4 M to 1.1 ϫ 10 Ϫ2 M, thiopentone exerted no effects over a comparable range of concentrations but was followed, however, by an abrupt and maximal inhibitory effect beyond the 2.5-fold concentration (Fig. 4) . This observation was confirmed by lower Hill coefficients for thiopentone effects on granulocyte recruitment (Ϫ4.8) and phagocytosis activity (Ϫ8.8) than for methohexitone on granulocyte recruitment (Ϫ1.3) and phagocytosis activity (Ϫ2.2).
Comparing the effect strength on the investigated variables, both barbiturates inhibited phagocytosis activity at lower concentrations than granulocyte recruitment. For thiopentone, the calculated concentration at which granulocyte recruitment was reduced to 50% (IC50) was 1.5 ϫ 10 Ϫ2 M; the IC50 for phagocytosis activity was 1.0 ϫ 10 Ϫ2 M. The corresponding values for methohexitone were 3.6 ϫ 10 Ϫ3 M for granulocyte recruitment and 1.1 ϫ 10 Ϫ3 M for phagocytosis activity, respectively.
DISCUSSION
Our data confirm a significant inhibition of granulocyte phagocytosis of viable S. aureus in the presence of barbiturates. Both granulocyte recruitment and phagocytosis activity were significantly attenuated at minimal concentrations of 7.6 ϫ 10 Ϫ3 M for thiopentone and 1.1 ϫ 10 Ϫ3 M for methohexitone. At higher concentrations, the two barbiturates caused nearly complete inhibition of the investigated variables. For thiopentone, the IC50 for granulocyte recruitment was 1.5 ϫ 10 Ϫ2 M, and the IC50 for phagocytosis activity was 1.0 ϫ 10 Ϫ2 M. The corresponding values for methohexitone were 3.6 ϫ 10 Ϫ3 M for granulocyte recruitment and 1.1 ϫ 10 Ϫ3 M for phagocytosis activity. In contrast, propofol was not observed to inhibit granulocyte recruitment or phagocytosis activity.
This study corroborates previous data on the inhibitory effect of thiopentone on phagocytosis of human leukocytes. Furthermore, our study expands these results to phagocytosis of live S. aureus, which is a predominant pathogen, especially in patients with brain trauma (9, 10) . More important, the results indicate substantial differences between the two barbiturates thiopentone and methohexitone with respect to their inhibitory potency and a differential pattern of inhibition.
However, our whole blood model with viable S. aureus is an in vitro assay, and the limitations of such a model should be considered. Mechanical manipulation, contact with foreign surfaces, and the lack of interaction with other cell types in tissues may alter phagocytosis. Besides this, phagocytosis is only one relevant part in the complex system of host defense, in which other components may compensate a depression of another component. Additionally, the lack of metabolism of the anesthetics by the liver and a potential interaction of metabolites with the host defense cannot be excluded. Furthermore, whole blood samples can only be incubated with barbiturates for a limited time. Compared with the clinical situation, these incubation times are rather short, considering that barbiturate sedation is applied over several days to control raised intracranial pressure. Additionally, blood was drawn from healthy volunteers and not from critically ill patients, so the results cannot be extrapolated to a clinical setting.
Thiopentone was previously shown to inhibit phagocytosis of heat-inactivated S. aureus and E. coli (6, 7, 18) . Davidson and coworkers (6) observed decreased phagocytosis in granulocytes at 7.6 ϫ 10 Ϫ3 M. The inhibition of phagocytosis at this concentration was confirmed by our data and expanded to viable S. aureus. In addition, our data show a strong dosedependent inhibition of granulocyte recruitment and phagocytosis activity beginning at concentrations of 7.6 ϫ 10
Ϫ3
M and leading to an almost complete inhibition of these two variables at 1.9 ϫ 10 Ϫ2 M. In contrast, Heller and coworkers (7) found inhibition of phagocytosis of fluorescence labeled E. coli at concentrations of only 7.6 ϫ 10 Ϫ5 M thiopentone. This discrepancy might be explained by the use of different strains of bacteria and different bacterial concentrations. Bacterial ingestion depends on the bacterial species, as identical amounts of S. aureus are ingested to a greater extent than E. coli (18) Additionally, granulocyte re- cruitment and phagocytosis activity of S. aureus depend directly on the bacterial concentration. Previously, we investigated the effect of local anesthetics on phagocytosis and applied a 5:1 ratio of bacteria to leukocytes (11) . In our present study, we used a ratio of 25:1 bacteria to leukocytes, which resulted in a marked increase in both granulocyte recruitment and phagocytosis activity and allowed a better calculation of doseresponse curves.
For methohexitone, our results demonstrate for the first time inhibitory effects on the phagocytosis of S. aureus at concentrations corresponding to only ten times those described in the clinical setting. Methohexitone showed a dosedependent inhibition over a broad dose range from 1.1 ϫ 10 Ϫ4 M to 1.1 ϫ 10
Ϫ2
M, whereas comparable dose ranges of thiopentone showed no inhibition, followed abruptly by maximal inhibition in a narrow concentration range just above these levels. Since intracellular pathways were not investigated in this study, this obvious difference cannot be explained by our results. It might be speculated, however, that thiopentone and methohexitone affect different pathways due to structural differences, possibly mediated by the sulfur-and the oxy-substituents (19) . Furthermore, barbiturates have been shown to inhibit protein kinase C activation, which plays a crucial role in cell membrane signal transduction and the regulation of inflammatory systems (20) , and for thiopenone an inhibition of nuclear factor-B, a transcription factor that plays a central role in the regulation of inflammatory gene expression, has been described (21, 22) . Conflicting results have been published for propofol (5) . Propofol in vitro did not affect lymphocyte proliferation (5) but has been shown to inhibit adhesion of platelets to leukocytes (23) , oxidative burst (24) , cytokine release (25), T-cell functions (5), and phagocytosis (5) (6) (7) . Our data corroborate the observation of Davidson and coworkers (6) , who found no inhibition of phagocytosis after 30 mins up to a concentration of 2.5 ϫ 10 Ϫ3 M. In contrast, inhibition of phagocytosis was described for E. coli in whole blood (2.75 ϫ 10 Ϫ5 M propofol) (24) as well as for S. aureus and E. coli in a model with isolated leukocytes (3.3 ϫ 10 Ϫ4 M propofol) (26) . In a rabbit model, bacterial clearance during propofol anesthesia was significantly attenuated (27) . However, a comparable effect was observed with the lipid vehicle, which induced enhanced organ colonization with E. coli. Since in our study no inhibitory effects could be observed even in the 100-fold clinical concentration, the effects of the lipid carrier were not investigated. It seemed unlikely that potential inhibitory effects of propofol in our study might be masked by the lipid carrier itself, since in the majority of studies in vitro, no or only minor inhibitory effects were observed for the lipid carrier (23, 24, 26, 28) . Again, the choice of different bacterial species and methodological differences between the studies seem to account for the observed differences.
In patients with increased intracranial pressure, barbiturates are usually applied until a burst suppression pattern is seen in the electroencephalographic monitoring. Here, the plasma levels are up to 40 times higher than after the induction of anesthesia, and the patients may receive such treatment for several days (12) (13) (14) (15) . These concentrations, however, are ten times lower than the minimal inhibitory concentrations that we observed for methohexitone and more than 100 times lower than the minimal inhibitory concentration of thiopentone. On the other hand, it has to be kept in mind that in the clinical setting the exposure to high barbiturate concentrations may be maintained over several days and various drug interactions can be expected, especially when additional immunosuppressive treatment such as corticosteroids is given.
Despite the fact that in our study inhibitory effects occurred in supraphysiological concentrations, an impact on the susceptibility to infectious complications in critically ill patients cannot be excluded. Our results might suggest that thiopentone-due to its lower inhibitory effects-should be preferred to metho- hexitone for sedation of patients with critically elevated intracranial pressure.
Since our study investigated a small aspect of the complex system of host defense, the fact that barbiturates may inhibit granulocyte functions deserves further attention and warrants clinical studies addressing this issue.
CONCLUSIONS
Our in vitro study using human leukocytes in a whole blood model shows different inhibitory effects of barbiturates on the phagocytosis of viable S. aureus, which is clinically one of the most relevant pathogens. In addition, our data allow a direct comparison of the inhibitory potency of thiopentone and methohexitone with concentration effect curves and suggest a more pronounced impact of methohexitone on granulocyte recruitment. This difference is even more dramatic with respect to phagocytosis activity.
However, the inhibitory effects occurred at dose ranges beyond the clinically observed plasma barbiturate concentrations and were observed in blood samples from healthy volunteers. Thus, direct extrapolation of these in vitro results to the clinical setting is not possible but should be the focus of future clinical trials, especially in critically ill or immunocompromised patients. Moreover, the differences between the two barbiturates deserve further attention both in investigations of molecular interactions and in clinical studies. 
